Copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Oct 26, 2023; 11(30): 7350-7362
Published online Oct 26, 2023. doi: 10.12998/wjcc.v11.i30.7350
Published online Oct 26, 2023. doi: 10.12998/wjcc.v11.i30.7350
Efficacy and safety of different anti-osteoporotic drugs for the spinal fusion surgery: A network meta-analysis
Xiao-Yuan He, Huan-Xiong Chen, Zhi-Rong Zhao, Spinal Surgery, Hainan Province Clinical Medical Center, Haikou 570100, Hainan Province, China
Author contributions: He XY He and Chen HX were responsible for research design, statistics and paper writing; Chen HX and Zhao ZR were responsible for the collation of data; all authors proofed the manuscript.
Conflict-of-interest statement: All the authors declare that they have no conflict of interest.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zhi-Rong Zhao, PhD, Professor, Spinal Surgery, Hainan Province Clinical Medical Center, The First Affiliated Hospital of Hainan Medical University, No. 31 Longhua Road, Haikou 570100, Hainan Province, China. yinmaosu19930611@163.com
Received: August 17, 2023
Peer-review started: August 17, 2023
First decision: August 30, 2023
Revised: September 10, 2023
Accepted: September 28, 2023
Article in press: September 28, 2023
Published online: October 26, 2023
Processing time: 68 Days and 18.2 Hours
Peer-review started: August 17, 2023
First decision: August 30, 2023
Revised: September 10, 2023
Accepted: September 28, 2023
Article in press: September 28, 2023
Published online: October 26, 2023
Processing time: 68 Days and 18.2 Hours
Core Tip
Core Tip: This network meta-analysis suggests that teriparatide combined denosumab and teriparatide significantly increased the fusion rate, decreased Oswestry disability index (ODI) without increasing adverse events. Based on current evidence, teriparatide combined denosumab and teriparatide are recommended to increase fusion rate and to reduce ODI in spinal fusion patients. However, the overall quality of evidence is low, the overall certainty of the evidence synthesis is low. In the future, there is a need for more high-quality randomized controlled trials to reassess or confirm this conclusion.